Werewolf Therapeutics, Inc.
Clinical trials sponsored by Werewolf Therapeutics, Inc., explained in plain language.
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…
Phase: PHASE1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cancer drug WTX-330 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…
Phase: PHASE1, PHASE2 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC